// App-Quantinova.ai

: Fatigue in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from the CIMPACT phase 3 trial

Researchers

Presenter

  • Alice B. Gottlieb

Principal Investigators

  • Jennifer Soung

  • Andreas Pinter

  • Tsen-Fang Tsai

  • Jose Manuel Carrascosa

  • Julia-Tatjana Maul

  • Saakshi Khattri

  • Nicola Tilt

  • Jose M. Lopez Pinto

  • Scarlett Hellot

  • Joseph F. Merola

Medical Centers

  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA

  • Southern California Dermatology Inc., Santa Ana, CA, USA

  • University Hospital Frankfurt, Frankfurt, Germany

  • Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

  • Dermatology Department, Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, IGTP, Badalona, Spain

  • Department of Neurology, University Hospital Zurich, Zurich, Switzerland

  • UCB Pharma, Slough

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Colombes, France

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

Locations

  • United States

  • Spain

  • Switzerland

  • United Kingdom

  • France

  • Germany

  • Taiwan

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT02346240

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved